Table 1.
Baseline characteristics of 267 HIV-seropositive active illicit drug users including physician experience
| Characteristic | All (267) | Physician experience | p-value |
|---|---|---|---|
| n (%) | Median (IQR3) | ||
| Gender | |||
| Male | 143 (53.6) | 41 (13-98) | 0.434 |
| Female | 124 (46.4) | 48 (13-130) | |
| Aboriginal ancestry | |||
| No | 162 (60.7) | 55 (15-103) | 0.716 |
| Yes | 105 (39.3) | 42 (10-116) | |
| DTES residence | |||
| No | 83 (31.1) | 28 (8-92) | 0.018 |
| Yes | 184 (68.9) | 56 (16-123) | |
| ART adherence | |||
| ≤ 95% in first year | 186 (69.7) | 42 (10-103) | 0.078 |
| > 95% in first year | 81 (30.3) | 58 (22-127) | |
| Methadone maintenance | |||
| No | 160 (59.9) | 38 (11-90) | 0.003 |
| Yes | 107 (40.1) | 60 (20-144) | |
| Daily cocaine use1 | |||
| No | 175 (65.5) | 59 (13-126) | 0.045 |
| Yes | 92 (34.5) | 34 (12-92) | |
| Daily heroin use1 | |||
| No | 196 (73.4) | 47 (13-104) | 0.658 |
| Yes | 71 (26.6) | 43 (14-116) | |
| PI2 in first ART regimen | |||
| No | 155 (58.1) | 44 (14-105) | 0.975 |
| Yes | 112 (41.9) | 58 (12-111) | |
1. Refers to the six-month period prior to baseline
2. Protease inhibitor
3. Inter-quartile range. Physician experience was defined as per 100 HIV-infected patients previously treated by that physician at the time each participant initiated ART.